Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study.

Seminars in arthritis and rheumatism - 1 Oct 2022

Zhao Sizheng Steven, Rajasundaram Skanda, Karhunen Ville, Alam Uazman, Gill Dipender

Abstract excerpt

OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce serum urate, but their efficacy depends on renal function which is often impaired in people with gout. SGLT1 is primarily expressed in the small intestine and its inhibition may be a more suitable therapeutic target. We aimed to investigate the association of genetically proxied SGLT1i with gout risk, serum urate levels and cardiovascular safety...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genome-Wide Association Study
Share to Glycated Hemoglobin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Uric Acid

Source

Identifiers

PMID: 35839537
DOI: 10.1016/j.semarthrit.2022.152058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study.PMID 35839537Read ↗

The effect of metformin on urate metabolism: Findings from observational and Mendelian randomization analyses.Semantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose.Semantic proximity Read ↗

Elucidating Genetic and Immunological Pathways Mediated by Sodium-Glucose Transporter 2 Inhibitors in Reducing Gout Risk: A Two-Step Mendelian Randomization Study.Semantic proximity Read ↗

Search for a Functional Genetic Variant Mimicking the Effect of SGLT2 Inhibitor Treatment.Semantic proximity Read ↗

The genetics of gout: translation into clinical practiceSemantic proximity Read ↗

Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases.Semantic proximity Read ↗

Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic RiskSemantic proximity Read ↗

MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank.Semantic proximity Read ↗

Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.Semantic proximity Read ↗

No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization studySemantic proximity Read ↗

Are polymorphisms affecting serum urate, renal urate handling and alcohol intake associated with co-morbidities in gout cases? A case-control study using data from the UK Biobank.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.